News
KZIA
9.50
+2.48%
0.23
Analysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR), Kazia Therapeutics (KZIA) and FocalTherics (FOCL)
TipRanks · 4d ago
Weekly Report: what happened at KZIA last week (0921-0925)?
Weekly Report · 09/28 09:07
Analyst Reiterates Buy on Kazia Therapeutics, Maintaining $40 Price Target as Paxalisib Advances into Rare Epilepsy Trial
TipRanks · 09/23 09:55
Kazia Therapeutics Gains $2 Million Milestone as Sovargen Doses First Paxalisib Patient in Rare Epilepsy Trial
TipRanks · 09/22 12:27
Kazia Therapeutics licensee doses first patient in Phase 1b/2a paxalisib trial
TipRanks · 09/22 11:40
Kazia Therapeutics Announces Sovargen Doses First Participant In Phase 1b/2a Clinical Study Of Paxalisib To Treat Epilepsies
Benzinga · 09/22 11:33
Weekly Report: what happened at KZIA last week (0914-0918)?
Weekly Report · 09/21 09:07
Kazia Therapeutics Switches ADR Depositary to JPMorgan as ADSs Remain on Nasdaq
TipRanks · 09/18 20:44
Weekly Report: what happened at KZIA last week (0907-0911)?
Weekly Report · 09/14 09:08
Kazia Therapeutics Price Target Maintained With a $40.00/Share by BTIG
Dow Jones · 09/10 13:23
BTIG Reiterates Buy on Kazia Therapeutics, Maintains $40 Price Target
Benzinga · 09/10 13:13
Kazia Doses First Patient In Phase 2 PNOC035 Study Of Paxalisib In Pediatric Brain Cancer; Stock Up
NASDAQ · 09/09 14:20
Kazia Therapeutics announces first patient dosed in PNOC035 study
TipRanks · 09/09 11:36
Kazia Therapeutics Doses First Participant In Its Arm A Of PNOC035 Platform To Evaluate Paxalisib In Combination With Gemcitabine Toi Treat Atypical Teratoid/Rhabdoid Tumor
Benzinga · 09/09 11:32
Weekly Report: what happened at KZIA last week (0831-0904)?
Weekly Report · 09/07 09:07
Kazia Therapeutics Unveils Preclinical Breakthrough for Paxalisib in Immunotherapy-Resistant Colorectal Cancer
TipRanks · 09/01 21:40
Kazia Therapeutics Is Maintained at Buy by BTIG
Dow Jones · 09/01 15:06
BTIG Maintains Buy on Kazia Therapeutics, Raises Price Target to $40
Benzinga · 09/01 14:56
Kazia Therapeutics price target raised to $40 from $34 at BTIG
TipRanks · 09/01 14:20
Kazia Reports Paxalisib Data In Immunotherapy-Resistant Colorectal Cancer
NASDAQ · 09/01 12:48
More
Webull provides a variety of real-time KZIA stock news. You can receive the latest news about Kazia Therapeuti through multiple platforms. This information may help you make smarter investment decisions.
About KZIA
Kazia Therapeutics Limited is an Australia-based pharmaceutical drug development company. The Company operates in the pharmaceutical research and development business. The Company’s lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. It is also developing EVT801, a small-molecule inhibitor of VEGFR3, which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. It designed paxalisib to inhibit PI3K, a critical control mechanism in growth and cell division, which is activated in many forms of cancer. The Company’s drug candidates are designed to treat diseases, such as brain cancer, renal cancer, and liver cancer.